/PRNewswire/ The Lung Cancer Mutation Consortium (LCMC), facilitated by the Lung Cancer Research Foundation (LCRF), announces the initiation of trial sites.
Face-to-face time: Adeleh Nejati
As an architecture undergraduate and summer intern, Adeleh Nejati’s first project was to measure every space in the hospital building to prepare drawings of existing conditions for the client. Walking on the building, seeing staff and patients interacting in different environments made her open her eyes to see how much the physical environment will have on physical and mental health and well-being, which left a deep impression on people. She decided to study at the Graduate School of the Health Research Center of Texas A&M University. Systems and design, specializing in healthcare design and planning.After graduating in 2014 and working in multiple companies, she joined HMC In 2019, she recently led the company’s COVID-19 and cancer research. She is busy outside the office with various hobbies, from hiking and cooking to new skills in playing the piano and skiing.
Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom's Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
About the Pivotal Trial of CLR 131 in Waldenstrom’s macroglobulinemia (WM)
The pivotal trial is designed as a global, non-comparator, single arm, expansion cohort of the currently ongoing Phase 2 CLOVER-1 study of CLR 131. The study will enroll 50 WM patients. Patients in the trial will receive up to four doses of CLR 131 over two cycles (cycle one days 1, 15, and cycle two days 57, 71). The primary endpoint of the trial is response rate as defined as a partial response (a minimum of a 50% reduction in the biological marker IgM) or better in patients that receive a minimum total body dose of 60 mCi with secondary endpoints of treatment free survival, duration of response and progression free survival. An independent data monitoring committee (iDMC) will perform an interim safety and futility evaluation on the first 10 patients enrolled. The assessment will occur patient by patient and will conclude after the tenth patient is evaluated; there is no planned study stoppage.
• Apr 23, 2021
Our guest on ST is Susan Neal, the Executive Director of Gilcrease Museum and the Helmerich Center for American Research here in Tulsa. Gilcrease Museum, as was recently announced, will be closing its doors at the end of its business day on July 4th. The museum s current structure will then be demolished, with construction of a new museum (on the same site) to follow. As Neal explains, construction of the new museum facility will begin in early 2022 and is expected to take 2 or 3 years. (More details are posted here.)